Calidi Biotherapeutics (CLDI) EBITDA (2022 - 2026)

Calidi Biotherapeutics has reported EBITDA for 5 years, with the latest figure at -$4.1 million in Q2 2026.

• On a quarterly basis, EBITDA rose 27.07% year-over-year to -$4.1 million in Q2 2026; TTM through Jun 2026 was -$18.9 million, a 3.75% increase from a year earlier, with the FY2025 full-year figure at -$19.9 million, up 7.11% from the prior year.
• EBITDA was -$4.1 million for Q2 2026 at Calidi Biotherapeutics, up from -$4.4 million in the prior quarter.
• The five-year high for EBITDA was -$361622.0 in Q2 2022, with the low at -$9.8 million in Q4 2023.
• Average EBITDA over 5 years is -$5.1 million, with a median of -$5.1 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: EBITDA tumbled 1707.69% in 2023, then soared 60.02% in 2024.
• Over 5 years, EBITDA stood at -$4.7 million in 2022, then plunged by 109.47% to -$9.8 million in 2023, then jumped by 60.02% to -$3.9 million in 2024, then declined by 11.36% to -$4.4 million in 2025, then rose by 7.11% to -$4.1 million in 2026.
• The last three EBITDA figures came in at -$4.1 million (Q2 2026), -$4.4 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.